We found that high expression of RAD21 increased the resistance of ovarian cancer cells to three PARP inhibitor types, and PARP inhibitor-induced cytotoxicity was augmented by inhibiting RAD21 expression. The gene discussed is RAD21; the disease is ovarian carcinoma.